Literature DB >> 11097390

MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis.

C Bartolozzi1, F Donati, D Cioni, L Crocetti, R Lencioni.   

Abstract

The objectives of this study were twofold: (a) to assess safety and tolerability of the hepatobiliary MR contrast agent MnDPDP; and (b) to investigate the sensitivity of MnDPDP-enhanced MRI, in comparison with dual-phase spiral CT, in the detection of hepatocellular carcinoma (HCC) in cirrhosis. Fifty patients with liver cirrhosis and histologically proven HCC were enrolled in a prospective phase-IIIB clinical trial. All patients underwent evaluation with dual-phase spiral CT and pre-contrast and post-contrast MRI at 1.5 T. The MR examination protocol included spin-echo (SE) and gradient-recalled-echo (GRE) T1-weighted images acquired before and 60-120 min after administration of 0.5 micromol/kg (0.5 ml/kg) MnDPDP (Teslascan, Nycomed Amersham, Oslo, Norway); and fast T2-weighted SE images obtained solely before contrast injection. Gold standard was provided by findings at Lipiodol CT in combination with follow-up spiral CT studies, which were repeated at 4-month intervals over a 10- to 27-month (mean +/- SD 20.1 +/- 5.1 months) follow-up period. No serious adverse event occurred. Eighty tumors ranging 0.8-9.1 cm in diameter (mean +/- SD 3.2 +/- 2.4 cm) were detected by Lipiodol CT or confirmed as cancerous foci by follow-up CT studies. Pre-contrast MRI detected 38 of 80 lesions (48%); MnDPDP-enhanced MRI, 65 of 80 lesions (81%); pre-contrast plus post-contrast MRI, 69 of 80 lesions (86%); and dual-phase spiral CT, 64 of 80 lesions (80%). The difference between unenhanced and MnDPDP-enhanced MRI was statistically significant (p < 0.001). The difference between MRI (pre-contrast plus post-contrast) and dual-phase spiral CT was not statistically significant (p = 0.33). The confidence in the final diagnosis, however, was significantly higher for MRI as compared with spiral CT (p<0.001). MnDPDP is a safe and well-tolerated hepatobiliary MR contrast agent. Magnetic resonance imaging with use of MnDPDP is significantly more sensitive than unenhanced MRI and as good as dual-phase spiral CT for detection of HCC in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11097390     DOI: 10.1007/s003300000564

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  13 in total

1.  Higher lesion conspicuity for SENSE dynamic MRI in detecting hypervascular hepatocellular carcinoma: analysis through the measurements of liver SNR and lesion-liver CNR comparison with conventional dynamic MRI.

Authors:  Osamu Tanaka; Hirotoshi Ito; Kei Yamada; Takao Kubota; Osamu Kizu; Takeharu Kato; Takuji Yamagami; Tsunehiko Nishimura
Journal:  Eur Radiol       Date:  2005-07-23       Impact factor: 5.315

2.  Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas.

Authors:  Young Kon Kim; Young Hwan Lee; Chong Soo Kim; Young Min Han; Seung Bae Hwang
Journal:  Eur Radiol       Date:  2007-04-03       Impact factor: 5.315

3.  Initial clinical experience with oral manganese (CMC-001) for liver MR imaging.

Authors:  Henrik S Thomsen; Jelle O Barentsz; Flemming Burcharth; Elizaveta Chabanova; Helena M Dekker; Flemming Moesgaard; Jakob M Moller; Per Leth-Espensen; Vibeke Logager; Satoru Takahashi
Journal:  Eur Radiol       Date:  2006-06-09       Impact factor: 5.315

4.  Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth?

Authors:  Johannes Zacherl; Peter Pokieser; Fritz Wrba; Christian Scheuba; Rupert Prokesch; Maximilian Zacherl; Friedrich Längle; Gabriela A Berlakovich; Ferdinand Mühlbacher; Rudolf Steininger
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

Review 5.  [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents].

Authors:  A Ba-Ssalamah; B Happel; J Kettenbach; A Dirisamer; F Wrba; F Längle; W Schima
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

6.  Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis.

Authors:  Luis Martí-Bonmatí; Amura F Fog; Bart Op de Beeck; Pauline Kane; Hans Fagertun
Journal:  Eur Radiol       Date:  2002-12-19       Impact factor: 5.315

7.  Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT.

Authors:  Carlo Bartolozzi; Francescamaria Donati; Dania Cioni; Carlo Procacci; Giovanni Morana; Antonio Chiesa; Luigi Grazioli; Giorgio Cittadini; Giuseppe Cittadini; Andrea Giovagnoni; Giovanni Gandini; Jochen Maass; Riccardo Lencioni
Journal:  Eur Radiol       Date:  2003-08-09       Impact factor: 5.315

8.  Percutaneous treatment of liver tumors with an adapted probe for cooled-tip, impedance-controlled radio-frequency ablation under open-magnet MR guidance: initial results.

Authors:  Alexis D Kelekis; Sylvain Terraz; André Roggan; François Terrier; Pietro Majno; Gilles Mentha; Arnaud Roth; Christoph D Becker
Journal:  Eur Radiol       Date:  2003-03-26       Impact factor: 5.315

Review 9.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

Review 10.  Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media.

Authors:  Carlo Bartolozzi; Laura Crocetti; Riccardo Lencioni; Dania Cioni; Clotilde Della Pina; Daniela Campani
Journal:  Eur Radiol       Date:  2007-02-16       Impact factor: 7.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.